Supreme Court orders a pharma marketing committee and sets a January hearing

The Supreme Court on Thursday directed the Union government to constitute a committee on unethical marketing by pharmaceutical companies. Justices Vikram Nath and Sandeep Mehta passed the order on a petition that had asked the Court to lay down guidelines until a statute exists. The bench said the committee will consider suggestions and representations and then recommend a course to the government. The case returns on 29 January, when the Centre has to file a compliance affidavit.

The order does not itself write the rules. It tells the government to finish a process the government had already described. On 8 September the Centre told the Court it was setting up a three-member panel to suggest a statutory framework, and it asked for two months. Thursday's hearing converts that statement into a direction, and it sets the date on which the Court will read the affidavit. A direction is harder to slip past than a submission. A missed affidavit on 29 January is a listed default.

What the petition asked for

The petitioners wanted the Court to regulate the field in the gap before a law. Indian drug marketing is governed by a voluntary code, the Uniform Code for Pharmaceutical Marketing Practices, administered by the department of pharmaceuticals. It covers gifts, travel, hospitality and inducements to doctors. It is not a criminal statute. Complaints go to an industry body and to the department. Penalties, where they exist, are suspension from the association rather than a prosecution. The petition's point was that a voluntary code has not stopped the practices it names.

The Centre, in the 8 September hearing, agreed that the mechanism needed to be stronger. Its filed position was that detailed discussions had been held and that a three-member committee would report on whether a statutory framework was needed and, if so, what it should contain. That is a narrower job than a judicial guideline. The Court on Thursday accepted that route and declined, for now, to write the code itself.

Why the January date matters

Two months from 8 September is early November. The Court has given the Centre until 29 January, a longer window than the one the government asked for, and has tied it to an affidavit rather than to an oral update. The committee's work, on the order, is to take suggestions and representations. Those will come from drug firms, from doctors' associations, and from the petitioners. A report that only restates the voluntary code will be measured against the petition's claim that the code has failed.

The practices at issue are concrete. Sponsored conference travel, samples tied to prescription volume, and paid speaking slots are the items earlier department audits and news investigations have listed. A statutory framework would move those items from an association rule to an offence or a licence condition. The Court has not chosen which. It has required a committee to recommend, and a government to answer on a fixed day.

What does not change this week

No company was fined on Thursday. No gift ban was written into a statute. Doctors may still be invited to meetings under the existing code. The change is procedural and dated. A committee the Centre promised on 8 September is now a committee the Court has ordered. The next public document is the compliance affidavit due on 29 January. If it names the three members and attaches a report, the case moves to the content of a law. If it does not, the bench has a missed direction to deal with, in a matter it has already refused to leave to a voluntary code.